65,437 trials
Respiratory Syncytial Virus Infection
Primary: Time-Weighted Average Change in Respiratory Syncytial Viral (RSV) Load From Baseline to Day 5 — -0.77; -0.89 log10 copies/mL — p=0.46
Familial Hypercholesterolemia
Primary: Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) — -45.5 Percent Change
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach — -0.56; -0.64; -0.74 Percent
Lung Cancer · Non Small Cell Lung Cancer · Solid Tumors
Primary: Response Rate (RR): — 38 tumors
Depression
Primary: Efficacy Assessed Using the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C) — -11.47; -9.35; -10.49 units on a scale
Lip Augmentation and Correction of Perioral Rhytids
Primary: Number of Participants With Adverse Events With the Use of Restylane Silk With Lidocaine — 11 Participants
Obesity · Sedentary Lifestyle
Primary: Change in Hours of Sitting Time — -70.1; 6.5 minutes
Facial Injuries · Tissue Injury
Primary: Total Fat Volume Injected and Facial Volume Postop — 11.4; 79.8; 49.6; 52.8 mL
Ventral Hernia · Incisional Hernia
Primary: Number of Participants With Hernia Recurrence — 0; 0; 0; 1 Participants
Healthy Volunteers
Primary: Number of Participants With Platelet Units Containing an Acceptable Residual WBC Level — 93; 93; 93; 0 Participants
Migraine
Primary: Safety - Number of Participants With Adverse Effects — 0; 13 Participants
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Primary: P2Y12 Reaction Units (PRU) - Part A — 301.6; 268.0; 295.4; 287.7 P2Y12 reaction units
HIV-1 Infection
Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons
Nausea · Vomiting
Primary: Occurrence of Intra-operative and Post-operative Vomiting — 30; 45 Participants — p=0.07
Athletic Injuries
Primary: Dermatologic Assessment at the Patch Application Site — 0.10; 0.04; 0.04; 0.06 Units on a scale